Since IL-6 is one of the key cytokines involved in an infection-induced cytokine storm, treating COVID-19 with tocilizumab is effective, especially in critically ill patients, as shown in the randomized, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia (REMAP-CAP) trial completed in 2021, which is one of the largest trials (n=803) on tocilizumab [6]. This evidence concerns the gene IL6 and COVID-19.